Vertex is still one of the top M&A targets

Analysts and healthcare experts have been looking at Vertex Pharmaceuticals as one of the next M&A targets for months. Chances for the Boston-based group to be taken over have become stronger than ever in the last days. Indeed, Vertex has announced that two investigational therapies for the treatment of cystic fibrosis (CF) will be tested in a Phase III clinical trial and in combination with Kalydeco–Vertex’s already available therapy–in order to treat at least 90% of CF cases. Indeed, both investigational treatments have already shown efficacy in increasing lung function by a minimum of 13% in a Phase II trial (July 2017).
Moreover, Vertex this week has published its 2017 results: revenues increased from $1.68bn to $2.17bn–that is 2% more than expected; EBITDA was $564m (26%), cash reserve reached $2.09bn. Vertex’s shares have risen 10.9% from the beginning of the year and 90% over the last 12 months (Nasdaq).